Clinical Trial

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-05.
Status change: Not Yet Recruiting → Recruiting 2025-02-19
Trial Details
NCT Number NCT06453902
Lead Sponsor Shenzhen TargetRx Co., Ltd.
Collaborators: Peking University People's Hospital, Henan Cancer Hospital, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Soochow University, Chinese Academy of Medical Sciences, First Affiliated Hospital of Zhejiang University, Shenzhen Second People's Hospital, Ruijin Hospital, Shengjing Hospital, Huazhong University of Science and Technology
Conditions Chronic Myeloid Leukemia, Accelerated Phase CML
Enrollment 40 participants
Start Date 2024-07-15
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-21